A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients
Masafumi Fukagawa; Keitaro Yokoyama; Takashi Shigematsu; Takashi Akiba; Akifumi Fujii; Takuto Kuramoto; Motoi Odani; Tadao Akizawa
Author Information: Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.